Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Afshineh Latifynia*, Mohammad Hossein Nicknam, Mohammad Javad Gharagozlou, Samad Farashi Bonab, Bita Ansaripour and Soror Charedar
Introduction: Leishmaniasis is a disease caused by the Leishmania major parasites and afflicted a large number of people every year. This disease is immunologically complex and in some cases, spontaneous improvement is achieved but in some others it enters the systemic phase. Therefore, it seems that the preparation of the vaccine is best suited to combat the disease.
Materials and methods: In this study, Balb/ C mice were vaccinated with new leishmaniasis vaccine and received booster dose one week later. Balb/c mice were challenged 1 week after booster dose. Almost 5 weeks later mice sacrificed. Final stages of preparation of the new L. major vaccine were evaluation of immunologic parameters in three injection groups (LT, LB and LBT) and two injection doses (100, 200 μg/0.1 ml) (totally six groups) post challenge with amastigote which removed from the wound (efficacy) and control group. Efficacy was measured by mice survival rate.
Results and discussion: In this study, the highest IL-4, IFN-γ and CD3+,CD4+, CD8+ and CD25+ were related to the LT group and highest IL-10 and IL-12 were also related to the control group. So it looks like that LT was best injection group and 100 and 200 μg/0.1 ml were best injection doses which recommended for future researches.
Published Date: 2023-02-16; Received Date: 2023-01-14